Hepatic Glycogenosis: An Underdiagnosed Entity?
diabetic keto acidosis
hepatic glycogenosis
liver biopsy
non-alcoholic fatty liver disease
type 1 diabetes mellitus (t1dm)
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
accepted:
05
04
2022
entrez:
9
5
2022
pubmed:
10
5
2022
medline:
10
5
2022
Statut:
epublish
Résumé
Hepatic glycogenosis (HG) is a rare complication of long-standing poorly controlled type 1 diabetes mellitus (T1DM), which is often misdiagnosed as non-alcoholic fatty liver disease (NAFLD). Despite the existence of several reports in the literature, it still is underrecognized, even among gastroenterologists. Differential diagnosis between these entities is essential since they have different prognoses. We report a case of an 18-year-old female, with a medical history of poorly controlled T1DM, admitted to an intensive care unit with severe diabetic ketoacidosis (DKA). Upon admission, aminotransferases were significantly elevated; bilirubin and coagulation tests were normal. Despite adequate DKA treatment, she had persistently elevated aminotransferases and hyperlactacidemia. Imaging studies showed hepatomegaly and bright liver parenchyma. Extensive laboratory workup was negative for other causes of liver disease. So, a liver biopsy was performed, which was consistent with the diagnosis of HG. Under strict metabolic control, she had progressive improvement, achieving biochemical normalization within 6 months. This case highlights the need for clinicians to be aware of this condition due to non-negligible differences between HG and NAFLD, with the latter progressing to fibrosis, and ultimately cirrhosis and hepatocarcinoma. On the opposite, HG is considered a benign condition, associated with an excellent prognosis that can be reversible after adequate metabolic control. Liver biopsy remains the gold standard method for HG diagnosis since it can distinguish it from NAFLD.
Identifiants
pubmed: 35530830
doi: 10.7759/cureus.23853
pmc: PMC9072257
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e23853Informations de copyright
Copyright © 2022, Garcês Soares et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Hepatobiliary Pancreat Dis Int. 2018 Apr;17(2):113-118
pubmed: 29709217
World J Diabetes. 2014 Dec 15;5(6):882-8
pubmed: 25512791
Clin Gastroenterol Hepatol. 2017 Jun;15(6):927-933
pubmed: 28043933
N Engl J Med. 2002 Apr 18;346(16):1221-31
pubmed: 11961152
N Z Med J. 2014 Apr 11;127(1392):95-7
pubmed: 24806252
Curr Opin Clin Nutr Metab Care. 2015 Jul;18(4):415-21
pubmed: 26001652
Endocr J. 2012;59(8):669-76
pubmed: 22673296
World J Hepatol. 2018 Feb 27;10(2):172-185
pubmed: 29527255
Am J Med. 2020 Feb;133(2):191-194
pubmed: 31369721
J Diabetes Complications. 2008 Sep-Oct;22(5):325-8
pubmed: 18413182
Hepatology. 2010 Feb;51(2):711-2
pubmed: 19957373
Case Rep Crit Care. 2016;2016:6072909
pubmed: 27699071
Am J Surg Pathol. 2006 Apr;30(4):508-13
pubmed: 16625098
Indian J Endocrinol Metab. 2013 Oct;17(Suppl 1):S283-5
pubmed: 24251187
Rev Esp Enferm Dig. 2016 Oct;108(10):673-676
pubmed: 26900767
Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):223-238
pubmed: 33349658
J Paediatr Child Health. 2000 Oct;36(5):449-52
pubmed: 11036799
World J Hepatol. 2018 Aug 27;10(8):530-542
pubmed: 30190781
Transplantation. 2007 Jan 15;83(1):84-6
pubmed: 17220798
Saudi Med J. 2017 Jan;38(1):89-92
pubmed: 28042636
Scand J Clin Lab Invest. 2013;73(4):293-9
pubmed: 23514017
J Hepatol. 2019 Oct;71(4):793-801
pubmed: 31279902
Ann Hepatol. 2012 Jul-Aug;11(4):554-8
pubmed: 22700639
World J Diabetes. 2015 Mar 15;6(2):321-5
pubmed: 25789113
Liver Int. 2021 Jul;41(7):1545-1555
pubmed: 33595181